Abstract Number: 1619 • ACR Convergence 2023
Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis
Background/Purpose: Infections are the leading cause of hospitalization and mortality in patients with ANCA vasculitis (AV). Multiple AV treatment guidelines recommend antimicrobial prophylaxis during treatment…Abstract Number: 2267 • ACR Convergence 2023
Explainable Machine Learning to Predict Hospitalized Infection in Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 1.85-fold higher risk of all-cause mortality and a 2.74 fold higher risk of infection-related mortality compared…Abstract Number: 136 • 2023 Pediatric Rheumatology Symposium
Incidence and Disease Burden of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis After Non-Pharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea
Background/Purpose: Several countries have implemented non-pharmaceutical interventions (NPIs) against the coronavirus disease 2019 (COVID-19) pandemic. We investigated the impact of NPIs on the incidence of…Abstract Number: 001 • 2023 Pediatric Rheumatology Symposium
Serious Infections Among Children with Systemic Lupus Erythematosus in the Pediatric Health Information System
Background/Purpose: High rates of serious infection have beenreported in pediatric systemic lupus erythematosus (pSLE), but modern care practices including pneumococcal vaccination, changing corticosteroid use, and…Abstract Number: 092 • 2023 Pediatric Rheumatology Symposium
Procalcitonin Levels in Patients with Juvenile Dermatomyositis Compared to Healthy Controls
Background/Purpose: Patients with JDM are at increased risk of infection due to increased aspiration risk and immunosuppression. Procalcitonin (PCT) is a biomarker of infection, that…Abstract Number: L16 • ACR Convergence 2022
Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)
Background/Purpose: Patients receiving glucocorticoids plus rituximab (RTX) show an increased risk of infection, especially invasive pneumococcal infections. Vaccine responses to influenza, Streptococcus pneumoniae and SARS-CoV-2…Abstract Number: 0769 • ACR Convergence 2022
Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial
Background/Purpose: Patients under immunosuppressive therapy have a high risk for severe COVID-19 disease courses. However, efficacy of vaccination and therefore the right vaccination strategy remains…Abstract Number: 1363 • ACR Convergence 2022
Impact of SARS-CoV-2 on the Clinical Presentation of Juvenile Idiopathic Inflammatory Myopathies
Background/Purpose: Viruses can trigger juvenile idiopathic inflammatory myopathies (JIIM), including juvenile dermatomyositis (JDM), juvenile polymyositis (JPM), and overlap myositis. There is growing evidence that infection…Abstract Number: 1750 • ACR Convergence 2022
Association Between Appendicitis and the Risk of Systemic Lupus Erythematosus: A Population-based, Case-control Study
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by diverse clinical manifestations. The risk factors of SLE included genetic factors and environmental…Abstract Number: 0779 • ACR Convergence 2022
Early Experience of Breakthrough COVID-19 Infections in Patients Who Received Pre-exposure Prophylaxis with Tixagevimab/cilgavimab
Background/Purpose: Patients receiving B cell depleting therapies (BCDT) for immune mediated inflammatory diseases (IMIDs) have high risk of poor COVID-19 outcomes and strategies for COVID-19…Abstract Number: 1365 • ACR Convergence 2022
Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database
Background/Purpose: FDA approved belimumab, the first targeted biological treatment for SLE, in March 2011 for adults with active, seropositive SLE receiving standard therapy. The indicated…Abstract Number: 1821 • ACR Convergence 2022
Colchicine and Other Gout Medications and the Risk of COVID-19 Infection, Hospitalization, and Subsequent Outcomes in People with Gout
Background/Purpose: To examine whether the use of colchicine and other gout medications is associated with the risk of COVID-19 infection, hospitalization, and subsequent outcomes in…Abstract Number: 0781 • ACR Convergence 2022
Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose
Background/Purpose: Rituximab (RTX) is a very effective treatment for autoimmune rheumatic diseases (AIRD). However, treatment increases risk of infections and impairs responses to vaccines. Prior…Abstract Number: 1396 • ACR Convergence 2022
Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database
Background/Purpose: Safety evidence of biological or targeted synthetic DMARDs (b/tsDMARDs) is still insufficient in older elderly ( >=75 years old (y/o)) patients with rheumatoid arthritis…Abstract Number: 1864 • ACR Convergence 2022
Hepatitis B Exposure and Infection in Idiopathic Inflammatory Myopathies: Prevalence, Presentation, and Treatment Response
Background/Purpose: Hepatitis B (HBV) screening in patients with autoimmune conditions is vital prior to the initiation of immunosuppressive therapy given the risk of HBV reactivation.…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 32
- Next Page »